Chronic liver disease includes viral hepatitis, alcoholic hepatitis, autoimmune liver disease, etc. Due to the chronic damage of long-term liver tissue, liver fibrosis is a common lesion characteristic of the liver, and further development of liver fibrosis can lead to cirrhosis or even liver cancer, which seriously affects patients’ health. Therefore, the assessment of the degree of liver fibrosis in chronic liver disease is a key aspect in judging the disease, deciding the treatment and following up the efficacy. The general diagnostic methods for liver fibrosis include liver puncture biopsy, various liver fibrosis serological index tests, liver color ultrasound and other imaging tests, but each of these diagnostic methods has its own advantages and disadvantages and is not sufficient for a comprehensive and accurate diagnosis of liver fibrosis. For example, liver puncture biopsy is considered the “gold standard” for determining the degree of liver fibrosis, but since liver puncture tissue only accounts for about 1/50,000 of the entire liver, it does not objectively reflect the whole liver, and liver puncture biopsy is an invasive test that can cause pain and certain risks. It is difficult to repeat the procedure many times. Wei Ping, Department of Infection, Wuhan Union Medical College Hospital In recent years, the FibroScan (transient elastography system) technology developed by France’s AcoustiMed has been widely used for the non-invasive diagnosis and evaluation of liver fibrosis. A large number of studies have confirmed that FibroScan can rapidly diagnose liver stiffness values with high accuracy and reproducibility, providing the possibility of early diagnosis, early treatment and prevention of liver fibrosis, and the technology is non-invasive, painless and completely avoids the trauma caused by liver puncture, which is easily accepted by patients. For chronic hepatitis B patients with low serum transaminase levels or asymptomatic patients, the transient elasticity technique can be used to detect the degree of liver fibrosis in the long-term management and follow-up of patients, and if progressive liver fibrosis is detected, they should receive antiviral treatment in time to avoid the development of cirrhosis and liver cancer, which is important to improve the efficacy and guide the treatment. Fibroscan is based on ultrasonography and uses transient elastography to measure liver stiffness and make a staging diagnosis of liver fibrosis in patients with chronic liver disease.Fibroscan has three key components: a transducer that generates ultrasound waves and acts as an ultrasound receiver; a probe located on the transducer that emits low-frequency vibrational waves; and a software program that can record data. Pulsed echo ultrasound measures the rate of low-frequency elasticity transmission in liver tissue, and a calculation can be performed to obtain the elasticity value of the tissue, expressed in kilopascals (kPa). The higher the elasticity value, the greater the stiffness value of the liver tissue. FibroScan is suitable for the examination of liver fibrosis and cirrhosis caused by various chronic liver diseases. However, studies have also found that Fibroscan has its own limitations, such as obesity, ascites, and extrahepatic cholestasis, which can affect the accuracy of the diagnosis. It is also not suitable for pregnant women, patients with pacemakers, or patients with ascites. In conclusion, Fibroscan is a new type of liver fibrosis test, which is a fast, convenient and non-invasive technique based on ultrasound diagnosis. By measuring the liver transient elastography to reflect the stiffness of the liver parenchyma, the degree of liver fibrosis can be assessed and quantitatively graded when the liver tissue shows fibrotic pathological changes.